Cutaneous hemangioma. D18.1
Conditions
Interventions
Intervention 1: Group 1: was treated with propranolol 2 mg per kg for six months. Intervention 2: Group 2: only are monitored.
Treatment - Drugs
Group 1: was treated with propranolol 2 mg per kg for six months
Group 2: only are monitored.
Sponsors
Arak University Of Medical Science
Eligibility
Sex/Gender
All
Age
78 Years to 93 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age under 15 years; numerous Hemangiomas; tumor size greater than 5 cm; Hemangioma on the face and nose. Exclusion criteria: age over 15 years; underlying heart disease; asthma; liver or kidney dysfunction; hypoglycemia; or low blood pressure due to drug use; consent to continue the study; the presence of compression lesion during the period under consideration.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size and color of blood sugar levels. Timepoint: 3 days, 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months. Method of measurement: Ultrasound and ruler. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrent lesions. Timepoint: 6 months after cessation of treatment. Method of measurement: Ultrasound and ruler. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. shabnam Hajiani Qotb Abadi
Arak University of medical science
Outcome results
None listed